Who We Are At ACCP

The ACCP is a professional organisation comprising of scientists and researchers working in comparative clinical pathology and safety assessment relevant to drug discovery and development.

 

The constitution of the Association for Comparative Clinical Pathology dictates that we will promote discussion to provide a better knowledge and understanding of all aspects of Comparative Clinical Pathology, including Haematology (peripheral blood and bone marrow), Clinical Biochemistry (including peripheral blood, urine and other assorted biological fluids), and Cytology. 

 

Prime functions of the ACCP are to promote education, train in the subjects and encourage the exchange of research and publication of data.

 

Members of the ACCP encourage professionalism in all aspects of their work and support membership of other professional bodies.

 

Members of the ACCP communicate,share methodologies and knowledge in the interests of furtherance of routine and specialist aspects of the work, helping each other to solve technical issues.

 

Committee Members

The society is made up of ten committee members.  Please select a team member you would like to know more about.

Peter Cotton

Catherine

Betts

Jo
Harding

Mike

Burgess-Wilson

Peter O'Brien

Ian Roman

Kam Seehra

Cliff Smith

Brenda Finney

Emilyanne Leonard 2018_edited.jpg

Emilyanne Leonard

 

Honours degree in Biology at Salford University graduating in 1979.  Medical Laboratory Scientific Officer in Clinical Pathology at an NHS Hospital with a senior position from 1986 specialising in Haematology. In 1989 I joined Zeneca Toxicology Laboratory as Head of Haematology with responsibility for the running of the laboratory, data interpretation and reporting out of all

pre-clinical toxicology studies on agrochemicals.

Peter Cotton

In 1998 I became Deputy Clinical Pathologist and Haematology Specialist at AstraZeneca Pharmaceuticals initiating the Investigative Flow Cytometry laboratory. 

 

In 2001 became a Senior Scientist within Clinical Pathology with responsibility for the resource of the department to support Clinical and pre-Clinical studies and also responsible for the data interpretation in pre-clinical toxicology studies. In 2005 to date I obtained the position of Clinical Pathology Laboratory Manager at AstraZeneca with specialist knowledge of toxicological Clinical Pathology.

I graduated from University of York with a BSc in cell biology and biochemistry in 1991 before undertaking a DPhil at York in the immune mechanisms deployed upon exposure of mice to an irradiated vaccine model of Schistosoma Mansoni.  I then undertook post doc in the Immunology group at Manchester University (1996-2000), again working on immune responses to parasites before starting in industry at the

Syngenta Central Toxicology Laboratory in a group looking at hypersensitivity responses and food allergy (2000-2007).

In 2007 I started at AstraZeneca in the Clinical Pathology Lab where I ran the immunoassay and immunotox group, investigating biomarkers of organ toxicity and adverse immune outputs.  I also undertook learning from the clinical pathology lab lead on interpreting various aspects of clinical chemistry and haematology outputs. More recently I have focussed on immunotoxicology endpoints for projects in the discovery & development pathway. I have been a committee member of the ACCP since 2013.

Catherine Betts
 

Following completion of my BSc Hons degree in Biomedical Technology from Sheffield Hallam University, I worked in the multi-disciplinary Clinical Pathology laboratory at Sanofi for 9 years, ultimately as Laboratory Head. During this time I completed a MSc degree in Biomedical Sciences at the University of Northumbria, and became a member of the ACCP, eventually joining the committee as Secretary.

Jo Harding

In 2004, I left the lab and took a role as study director with responsibility for General Toxicology studies at Covance, whilst maintaining an interest and specialism in clinical pathology data interpretation, and choice of biomarkers on Toxicology studies. More recently, I have taken a new position as a Project Toxicologist at AstraZeneca. Throughout my career I have maintained my association with the ACCP and I am a strong supporter of the training, education, and information-sharing philosophy of the association.

Michael, PhD, DMLM was born in England, trained in Nottingham as a Medical Laboratory Scientist in the disciplines of Haematology, Blood Transfusion and Blood Coagulation and studied for the Fellowship Examination in Haematology. In 1978 joined the University Department of Medicine researching Coagulation and Platelet behaviour. In 1986 managed the Coagulation Laboratory in the University Hospital Nottingham. Between 1990 and 1995 worked as Research Scientist for Baxter Dade in Switzerland developing coagulation assays. 

Between 1995 and 1999 worked as Research Scientist for J&J, Milpitas California developing a coagulation POCT device. In 1999 moved back the UK as Haematology Laboratory Manager at Northampton General Hospital. In 2010 moved to the CRO Huntingdon Life Sciences as Haematology Team Leader, and presently Haematology Principal Scientist at Envigo (formally HLS). Joined the ACCP in 2010 and presently serving on the committee as membership secretary. Have supported ACCP conferences and given blood and bone marrow microscopy training courses and lectured at the Toxicology Course at the University of Surrey and ACCP meetings.

Michael
Burgess-Wilson
 

My career started in the NHS in 1983 where I spent time in all laboratory disciplines, ranging from Haematology, Blood Transfusion, Immunology, Clinical Chemistry, Microbiology and Histology. I then specialised in Haematology and Transfusion Science and studied for my Fellowship in Immunology. In 1989 I joined Glaxo Haematology department where I studied for my MSc in Haematology and Transfusion Science.​

Ian Roman

After the Glaxo Welcome merger Haematology and Clinical Chemistry merged and I joined the combined Clinical Pathology investigative group specialising in flow cytometry. When Glaxo and SmithKline Beecham merged I stayed in Clinical Pathology with responsibility for Haematology. I’m now head of the Clinical Pathology and Diagnostics Department of Glaxo Smithkline UK. I was part of the ACH from 1990 prior to the merger with the ACCA to become the ACCP. I eventually joined the committee of the ACCP and have been part of the group who lecture on the Toxicology MSc course at the University of Surrey as well as part of the team who run the data interpretation course of the ACCP.

Peter O’Brien, PhD, DVSc, Diplomate ECVCP was born in Toronto Canada of Irish and English parents. He got veterinary training in Canada, PhD at Minnesota, and certification in vetclinpath at Ontario’s Vet College. After 7 years here, he moved into tox and headed toxclinpath at P&G-Cincinnatti, then SmithKline-Beecham-Welwyn, then Pfizer-Sandwich

After 11 years in tox, he returned to academia where he serves as Clinical Pathologist at Dublin Vet School.  Peter is past president of ESVCP, ECVCP and EBVS. In 2008, he established ADL, for specialised (tox) clinpath testing.

 

His >100 research papers focus on cardiac, muscle, liver and pancreatic biomarkers. He attended ACCP meetings from the 1997 ACH Morpeth conference. He joined ACCA then ACCP committees since 1998 and is currently Scientific Secretary. His role has been with conference management and education for all the above organisations.

Peter O'Brien
 

I joined the Clinical Pathology Department of East Birmingham Hospital in 1971 as a trainee Medical Laboratory Technician. Qualifying with an HNC and Final Exam of the IBMS in 1975, and taking the Special examination of the IBMS, I worked in Haematology and Blood Transfusion medicine performing phlebotomy, all routine Haematological and blood coagulation tests, cross matching and antibody identification during my 15 years service. 

Cliff Smith

I moved to a senior post at Hazleton Laboratories in Harrogate to perform routine Haematology on animals, and developed specialist areas of Toxicological investigation and Phase I - III clinical trials covering the next 30 years. Specialist areas included bone marrow analysis, platelet function testing, flow cytometry, and ELISPOT. During this time I achieved promotion to Head of Haematology and deputised for the laboratory manager in their absence. Hazleton then went through a variety of incarnations ending up as Covance today. All through my career I was a member of the IBMS and state registered with the Health Professions Council, and for the last 30+ years, a committee member of the ACCP.

Kam is a Principal Scientist at Envigo involved with the development of the biomarker portfolio providing scientific support, advising on method design and in managing studies. Kam has a background in the medical sciences and cell signalling, with experiences in cell-based assays, fluorescent imaging, flow cytometry and proteomics. Kam’s career commenced in the industry in 2002 at Astrazeneca,

Charnwood working as a research scientist in the field of chronic obstructive pulmonary disease (COPD) on a project involving human lung mast cells.  After completion of her PhD investigating vascular endothelial growth factor (VEGF) and integrin crosstalk in angiogenesis, she moved into playing a central role in the translational medicine group at AstraZeneca, Alderley Park in 2006, investigating cytotoxic compounds against standard-of-care chemotherapy supporting Phase I clinical trials.

 

Kam holds an honours degree in the Medical Sciences from the University of Birmingham, an MSc in the Biomedical Sciences, and a PhD in Molecular Biology awarded by the University of Nottingham.  She has been a committee member for the ACCP since 2009.

Kam Seehra
 

I graduated from The University of North Carolina at Chapel Hill with a BSc of Clinical Laboratory Science in 2011. I was certified as a Clinical Laboratory Scientist in August of 2011 by the American Society for Clinical Pathology.

Emilyanne Leonard

From 2011 to 2013, I was a Medical Laboratory Scientist at High Point Regional Hospital, where I worked in all lab departments as a generalist- Haematology, Blood Bank, Clinical Chemistry, Coagulation, and Urinalysis.

I moved to London in 2013 to pursue a MSc at Kingston University, and graduated with distinction in 2015 with a MSc of Biomedical Science with a focus in Haematology.

I joined AstraZeneca in 2015 as a Senior Scientist in the Clinical Pathology team, running and interpreting routine haematology and clinical chemistry panels as well as other non-routine biomarkers for in house pre-clinical rat toxicological studies. In 2017, our team within AZ shifted its focus to the more bespoke biomarkers utilized in pre-clinical studies, using methods such as flow cytometry and immunoassays. I continue to support the in vivo rat safety studies with non-routine biomarker data as well as providing select biomarker support to in vitro studies.

Brenda did her PhD at Cardiff University in Biomedical Sciences, focusing on the role of calcium and the extracellular calcium sensing receptor in lung development. This was followed by a post-doc in The Platelet Group at the

University of Birmingham where she characterised the developmental phenotype of transgenic mouse lines used for platelet signalling investigations. During this position she moved into performing in vivo microscopy of platelet activation and aggregation. She joined Sequani in 2013 and worked with the Pathology Sciences team before becoming part of the Biomarkers group in 2014. In 2017 she became the Principal Scientist for the Biological Sciences department and now provides scientific oversight for Clinical Pathology, In Vitro Toxicology and Histology. She has experience in a wide range of analysis techniques, but has in the past few years been focusing on the validation and use of immunoassays and immunophenotyping within a GLP-registered setting. She became involved with the ACCP in 2016, is an associate editor for the journal Comparative Clinical Pathology, and is also a member of the BTS. 

Brenda Finney